GlobalSCAPE Inc
Change company Symbol lookup
Select an option...
GSB GlobalSCAPE Inc
IVR-B Invesco Mortgage Capital Inc
EWBC East West Bancorp Inc
RVNC Revance Therapeutics Inc
ZFGN Zafgen Inc
SFOR StrikeForce Technologies Inc
SPLV Invesco S&P 500® Low Volatility ETF
USMV iShares Edge MSCI Min Vol USA ETF
HULYX Hawaiian Tax-Free Trust Class Y
ORNCD Oranco Inc
Go

Information Technology : Software | Small Cap BlendCompany profile

GlobalSCAPE, Inc. provides secure information exchange capabilities for enterprises and consumers through the development and distribution of software, delivery of managed and hosted solutions, and provisioning of associated services. The Company's primary product is Enhance File Transfer (EFT). Its software products and services include Managed File Transfer Solutions (MFT), Secure Content Mobility Solutions, Wide Area File Services (WAFS), Managed E-Mail Attachment Solution, Consumer-Based File Transfer Solution and professional services. Its solution portfolio facilitates transmission of critical information, such as financial data, medical records, customer files, vendor files, personnel files, transaction activity and other similar documents. The Company enables transmission of critical information using servers, desktop and notebook computers, and a range of network-enabled mobile devices. Its products also provide customers to monitor and audit file transfer activities.

Closing Price
$11.84
Day's Change
-0.06 (-0.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.07
Day's Low
11.62
Volume
(Light)
Volume:
115,437

10-day average volume:
195,874
115,437

UPDATE: Cannabis stocks fall after FDA hearing on CBD finds conflicting views of substance

7:43 am ET June 5, 2019 (MarketWatch)
Print

By Ciara Linnane, MarketWatch

Hearing 'highlighted messy state of the industry, with widespread use of CBD products with minimal standardization,' says analyst

Cannabis stocks were mostly lower Monday, as investors digested the first reports from Friday's regulatory hearing on cannabis and its ingredients and the news that Illinois is legalizing weed for adult recreational use.

The U.S. Food and Drug Administration conducted its first-ever hearing (http://www.marketwatch.com/story/cannabis-stocks-slide-as-fda-hearing-on-cannabis-and-its-ingredients-kicks-off-2019-05-31)on cannabis and its nonintoxicating ingredient CBD all day Friday with more than 100 speakers offering views, including researchers, health professionals, advocates, manufacturers and opponents.

The hearing came after hemp was legalized in the 2018 Farm Bill, leading to a crop of hemp-based products being sold online and in stores, including at mom-and-pop stores. But CBD, which is widely held to have wellness properties, particularly in treating pain, inflammation and anxiety, was not included in the lifting of the federal ban and was instead placed under the regulatory purview of the FDA. That's because it's the key ingredient in the only cannabis-based drug to win FDA approval, GW Pharmaceuctical's PLC's (GWPH) Epidiolex, a treatment for severe forms of childhood epilepsy.

The FDA has warned companies that because it views CBD as a drug, it cannot be added to food or beverages or marketed as a dietary supplement in interstate commerce. But it has also said that given the strong public interest in CBD as a wellness aid, it will seek to help provide pathways to regulatory approval.

Don't miss:An entire industry is being built around CBD, but we really don't know that much about it (http://www.marketwatch.com/story/an-entire-industry-is-being-built-around-cbd-but-we-really-dont-know-that-much-about-it-2019-05-15)

The hearing "highlighted the messy state of the industry, with widespread use of CBD products with minimal standardization, evidence for benefit and understanding of safety profile," said Evercore ISI analysts led by Josh Schimmer in a note to clients.

See also: More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits (http://www.marketwatch.com/story/some-baby-boomers-say-doctors-arent-giving-them-enough-information-about-cannabis-2019-06-03)

The discussion was "at times quite absurd with outlandish claims, inconsistent messages and an undercurrent of potential safety concerns," said the analyst. It was however quite favorable for GW Pharma, as the FDA made clear that it wants to ensure the substance continues to be subjected to clinical research, he wrote. GW Pharma shares offered a rare glimpse of green in the cannabis sector Monday, gaining 1.1%.

Read: This company wants to be the Bacardi of cannabis -- and it has plans for an IPO (http://www.marketwatch.com/story/this-company-wants-to-be-the-bacardi-of-cannabis-and-it-has-plans-for-an-ipo-2019-05-24)

"Considering the extent to which the CBD cat is out of the bag, it remains to be seen how the FDA will regulate this industry; it might not have adequate resources to fully monitor and police it," said Schimmer.

Cannabis Watch: For more of MarketWatch's coverage of cannabis companies (http://www.marketwatch.com/storyno-meta-for-guid)

At CIBC, analysts noted that a World Health Organization report found CBD to be safe and nonaddictive, although they acknowledged that most experts fret there is still insufficient data from trials. What is clear is the strong demand for CBD, they wrote in a note to clients, citing a speaker at the hearing from Consumer Reports, who said that about 65 million Americans have tried CBD and 63% found it effective.

"Furthermore, more Americans' primary concern was pricing rather than safety," said the note.

Many of Friday's speakers underscored the need for quality testing and safety standards, as much of the CBD currently available is substandard or mislabeled with incorrect amounts of CBD or even THC, the intoxicating ingredient in cannabis, as well as impurities including pesticides and bacteria. CIBC is expecting more clarity from the FDA in the coming year.

Separately, Illinois will become the 11th state to fully legalize cannabis, after the state House passed a bill on Friday (https://www.chicagotribune.com/politics/ct-met-illinois-recreational-marijuana-legislation-20190531-story.html) that will now pass to Gov. J.B. Pritzker who has said he would sign it. Sales are expected to start in January of 2020.

See also:In 'the marijuana ghetto' at Davos, Canopy Growth found its American pot partner (http://www.marketwatch.com/story/in-the-marijuana-ghetto-at-davos-canopy-growth-found-its-american-pot-partner-2019-05-23)

Alliance Global Partners analyst Aaron Grey said the state is the first to achieve legalization involving retail stores through the legislative process and may serve as a template for other states seeking to do the same. New York, New Jersey, Connecticut, Maine and New Hampshire are all trying to agree on legislation without resorting to the ballot process.

Illinois sales could reach $2.9 billion in five years, said Grey, and have another important effect.

"We believe the passing of adult-use retail sales in Illinois could serve as a catalyst for other states evaluating similar bills to follow suit, and also put further pressure to address the disconnect between state and federal law as 29% of the U.S. population will now live in a state where adult use cannabis is legal (with nearly 70% living in a state where medical cannabis is legal)," he wrote in a note.

Among individual stocks, he expects KushCo Holdings Inc. (KSHB) to benefit from the news, "from increased demand of cannabis supplies from MSOs (multistate operators) and other manufacturers and dispensary operators. He also expects Canadian player Canopy Growth Corp(WEED.T)(WEED.T) to benefit as Acreage Holdings Inc., which Canopy is planning to acquire, has a medical license for Illinois, "providing the company an early mover advantage in adult-use retail sales."

KushCo shares were down 2.4%, while Canopy was down 2%.

Tilt Holdings Inc. shares (TILT.L) were down 6.3%, after the company, which took a $500 million writedown in early May, (http://www.marketwatch.com/story/how-a-freshly-grown-cannabis-company-managed-to-lose-500-million-in-less-than-a-month-2019-05-02)published financials last week (https://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00046470&issuerType=03&projectNo=02926793&docId=4537484)that showed its stock-based compensation at about $60 million. The company had a net loss of $77.9 million for the three months to end March, wider than the $2.1 million posted in the year-earlier period. Revenue came to $34.4 million.

Elsewhere in the sector, Tilray Inc. shares(TLRY) fell 4.5%, Aurora Cannabis Inc. (ACB.T) (ACB.T) was down 2.7% and Cronos Group Inc. (CRON.T) (CRON.T) was down 2.3%.

Valens GroWorks Corp.was down 4.7%, Organigram Holdings Inc.was down 2.1% and Aleafia Health Inc. (ALEF.T) (ALEF.T) was down 2.8%.

Green Growth Brands Inc.was down 6.9%. Aphria Inc. (APHA.T) (APHA.T) was down 2.9% and Green Organic Dutchman Holdings Inc.(TGOD.T)(TGOD.T) was down 1.2%.

Read:How living near a marijuana dispensary affects your home's price (http://www.marketwatch.com/story/on-420-consider-how-living-near-a-marijuana-dispensary-affects-your-homes-price-2019-04-20)

The Horizons Marijuana Life Sciences ETFwas down 1.9%, and the ETFMG Alternative Harvest ETF(MJ)was down 1.7%.

The Dow Jones Industrial Average was up 0.02% and the S&P 500 was down 0.3%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 05, 2019 07:43 ET (11:43 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.